Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis

BMJ (Online)

Volumn 339, Issue , 2009, Pages

  Latimer, Nicholas ^a   Lord, Joanne ^b   Grant, Robert L ^c   O'Mahony, Rachel ^c   Dickson, John ^d   Conaghan, Philip G ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^d Guisborough Primary Care Hospital   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PROTON PUMP INHIBITOR;

ADULT; ADVERSE EVENT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG UTILIZATION; DYSPEPSIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MIDDLE AGED; OBSERVATIONAL STUDY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; SYMPTOMATIC ULCER; SYSTEMATIC REVIEW (TOPIC); THERAPY EFFECT; TREATMENT RESPONSE; ULCER; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; HUMANS; OSTEOARTHRITIS; PROTON PUMP INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 68549090917     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b2538     Document Type: Article

References (51)

1. Prescription Pricing Authority. Prescription Pricing Authority Newsletter. March 2005, pg 2-4. http://www.ppa.org.uk/pdfs/imPACT/imPACT% 20March%202005.pdf (accessed 29 April 2008).
2. National Health Service National Prescribing Centre. Cardiovascular and Gastrointestinal safety of NSAIDs. MeReC Extra Issue No. 30, November 2007. http://www.npc.co.uk/MeReC-Extra/2008/no30-2007.html#CVR(accessed 29 April 2008).
3. Medicines and Healthcare products Regulatory Agency. Cardiovascular safety of COX-2 inhibitors and non-selective NSAIDs. 15 April 2008. http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Productspecificinformationandadvice/CardiovascularsafetyofCOX-2inhibitorsandnon-selectiveNSAIDs/index.htm (accessed 29 April 2008).
4. Mayor S. US heart group says COX 2 inhibitors should be last choice for pain relief in patients at risk. BMJ 2007;334:441.
5. Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006;10:iii-iv,xi-xiii,1-183.
6. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX 2 inhibitors. Am J Gastroenterol 2006;101:701-10.
7. Chan FK,Wong VW, Suen BY,Wu JC, Ching JY, Hung LC, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007;369:1621-6.
8. National Institute for Health and Clinical Excellence. Guidance on the use of Cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology Appraisal Guidance no 27, July 2001. http://www.nice.org.uk/nicemedia/pdf/coxiifullguidance.pdf (accessed 29 April 2008).
9. ChenY-F, JobanputraP, BartonP, BryanS, Fry-SmithA, HarrisG, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12:1-278, iii.
10. National Collaborating Centre for Chronic Conditions (NCCCC) on behalf of the National Institute for Health and Clinical Excellence. Osteoarthritis: National clinical guideline for care and management in adults. London: Royal College of Physicians, February 2008, http://www.nice.org.uk/nicemedia/pdf/CG059FullGuideline.pdf(accessed 29 April 2008).
11. Conaghan P, Dickson J, Grant R on behalf of the Guideline Development Group. Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ 2008;336:502-3.
12. Maetzel A, Krahn M, Naglie G. The cost-effectiveness of celecoxib and rofecoxib inpatients with osteoarthritis or rheumatoid arthritis. Technology Report no 23. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2001.
13. National Health Service Business Services Authority Prescription Pricing Division. National Health Service England and Wales Electronic Drug Tariff. February 2008. http://www.ppa.org.uk/edt/February-2008/mindex.htm (accessed 19 February 2008).
14. National Institute for Health and Clinical Excellence. The Guidelines Manual. April 2007. http://www.nice.org.uk/niceMedia/pdf/GuidelinesManualAllChapters.pdf (accessed 29 April 2008).
15. Silverstein FE, Faich G. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
16. United States Food and Drug Administration.Medical Officer Review: Celebrex (celecoxib). NDA 20-998/S-009. 20 September 2000. http://www.fda.gov/ohrms/dockets/AC/01/briefing/3677b1-03-med.pdf (accessed 19 May 2008).
17. Farkouh ME, Kirschner H. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.
18. Schnitzer TJ, Burmester GR, Mysler E. Comparison of lumiracoxibwith naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
19. Novartis. Prexige (Frexocel, Hirza, Stellige) (lumiracoxib, COX189). Drug Regulatory Affairs, Clinical Development & Medical Affairs, Clinical Epidemiology & Safety. 15 December 2006. http://www.mhra.gov.uk/home/idcplg? IdcService=GET-FILE&dDocName=con2022709&RevisionSelection Method=Latest (accessed 25 June 2009).
20. Laine L, Curtis SP, Cryer B, Kaur A, Cannon C. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;369:465-73.
21. Laine L, Curtis S, Bombardier C, Weinblatt ME, Kaur A, Cannon CP, et al. Clinical Outcomes following long term treatmentwith etoricoxib versus diclofenac in 34,701 patients with osteoarthritis or rheumatoid arthritis: primary results of the multinational etoricoxib and diclofenac arthritis Long-term (MEDAL) program. Presentation L37. Program and Abstracts of the American College of Rheumatology 2006 Annual Meeting; 11-15 November 2006; Washington, DC.
22. Medicines and Healthcare products Regulatory Agency (MHRA). Pharmacovigilance Working Party (PhVWP) Assessment Report. Etoricoxib, Diclofenac. London: MHRA,September 2006.
23. National Collaborating Centre for Chronic Conditions (NCCCC) on behalf of the National Institute for Health and Clinical Excellence. Osteoarthritis: National clinical guideline for care and management in adults, Appendix D: Details of the NSAID/COX-2 inhibitor health economic model. London: Royal College of Physicians, February 2008.
24. Maetzel A, Ferraz MB, Bombardier C. The cost effectiveness of misoprostol in preventing serious gastrointestional events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998;41:16-25.
25. National Institute for Health and Clinical Excellence. Hypertension. Management of hypertension in adults in primary care: partial update. London: NICE, 2006.
26. Rodriguez LAG, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-6.
27. Kearney PM, Baigent C,Godwin J,Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-05.
28. MamdaniM, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G. Cyclooxygenase-2 inhibitors versus nonselective non-steroidal antiinflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363:1751-6.
29. Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol 2006;47(Suppl 1):60-66S.
30. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;331:1310-6.
31. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.
32. Bloor K, Maynard A. Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs? Pharmacoeconomics 1996;9:484-96.
33. Briggs A. Handling uncertainty in economic evaluation. BMJ 1999;319:120.
34. Department of Health. NHS reference costs 2005-06. London:DH, 2006.
35. Curtis L, Netten A. Unit Costs of Health & Health Social Care. Kent: University of Kent, 2006.
36. British National Formulary. 53rd ed. London: BMJ Publishing and Royal Pharmaceutical Society of Great Britain, 2007.
37. Bellamy NW, Buchanan W, Goldsmith C, Campbell J, Stitt L. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
38. Segal L, Day S, Chapman A, Osborne R. Priority setting in osteoarthritis. Melbourne: Monash University, 2003.
39. Barton GR, Sach T, Jenkinson C, Avery A, Doherty M, Muir KR. Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health Qual Life Outcomes 2008;6:51.
40. Pickard A, Johnson J, Feeny D. EQ-5D. Responsiveness of generic health-related quality of life measures in stroke. Qual Life Res 2005;14:207-19.
41. Center on the Evaluation of Value and Risk in Health. Preference weights 1998-2001. Institute for Clinical Research and Health Policy Studies, Tufts-New England Medical Center, Boston, MA. http://www.tufts-nemc.org/cearegistry/(Accessed 29 April 2008).
42. Department of Health. Health Survey for England. London: DH, 1998.
43. Andersohn F, Schade R, Suissa S,Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006;37:1725-30.
44. Medicines and Healthcare products Regulatory Agency. Pharmacovigilance Working Party (PhVWP) Assessment Report. Diclofenac, Ibuprofen, Naproxen. London: MHRA, 2006.
45. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98:266-74.
46. Dieppe P, Cushnaghan J, Jasani MK, McCrae F, Watt I. A two-year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint. Br J Rheumatol 1993;32:595-600.
47. Scott DL, Berry H, Capell H, Coppock J, Daymond T, Doyle DV, et al. The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. Rheumatology 2000;39:1095-101.
48. Williams HJ,Ward JR, Egger MJ, Neuner R, Brooks RH, Clegg DO, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993;36:1196-206.
49. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The costeffectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003;138:795-806.
50. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83.
51. Yang YX, Lewis JD, Epstein S, Metz D. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53.